Suven Life Sciences Ltd has submitted an application with Drug Controller General of India for grant of permission to undertake phase-I clinical trials with their investigational New Drug (IND) SUVN-502.

SUVN-502 is novel, potent, safe, highly selective and orally active antagonist at a central nervous system (CNS) serotonin receptor site 5-HTs intended for the treatment of cognitive disorders such as Alzheimer's and Schizophrenia.

Treatment for Alzheimer's disease and Schizophrenia is an unmet medical need. The company's primary focus is to discover drugs that address significant unmet medical needs.

The company is committed to neuroscience research and for development of new treatments for neurological disorder. The company's discovery research focuses on CNS disorders through novel mechanisms using small-molecule medical chemistry approaches. The company's CNS drug discovery scientists at Hyderabad, India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, schizophrenia, depression, cognitive disorders and neurodegeneration.

The Company is pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995, "drug discovery and development support services" (DDDSS) since 2005, and Collaborative Research Partner" (CRP) with global pharma majors since 2006.